Clinical optical coherence tomography for retinal metabolic imaging

用于视网膜代谢成像的临床光学相干断层扫描

• 批准号: 9466775
• 负责人: Roman Kuranov
• 金额: $ 61.76万
• 依托单位: OPTICENT, INC.
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9466775
• 关键词: Age; Age related macular degeneration; Algorithms; Anatomy; Background Diabetic Retinopathy; Biological Markers; Blindness; Blood capillaries; Blood flow; Caring; Clinical; Clinical Management; Clinical Research; Collaborations; Complications of Diabetes Mellitus; Data; Development; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Disease; Engineering; Failure; Feedback; Functional Imaging; Functional disorder; Glaucoma; Goals; Health; Hemoglobin; Hospitals; Human; Image; Imaging technology; Intervention; Ischemia; Lasers; Lead; Legal patent; Licensing; Light Coagulation; Low-Level Laser Therapy; Measures; Medical center; Metabolic; Modernization; Monitor; Monitoring for Recurrence; New York; Ophthalmologist; Ophthalmology; Optical Coherence Tomography; Outcome; Oxygen; Patients; Peripheral; Phase; Photoreceptors; Positioning Attribute; Protocols documentation; Recording of previous events; Retina; Retinal; Retinal Detachment; Retinal Diseases; Retinopathy of Prematurity; Rodent Model; Role; Scientist; Secure; Severities; Signal Pathway; Structure; Technology; Testing; Time; Traction; Translations; Universities; Vascular blood supply; Visible Radiation; Vitreous Hemorrhage; Work; angiogenesis; base; bevacizumab; clinical application; clinical practice; design; diabetes management; functional disability; high risk; human subject; improved; instrument; mathematical analysis; meetings; metabolic imaging; metabolic rate; non-invasive imaging; non-invasive monitor; novel; proliferative diabetic retinopathy; prototype; response; retinal imaging; retinal ischemia; retinal neuron; technology development; tool; usability

PROJECT SUMMARY Diabetic retinopathy (DR) is a complication of diabetes and a leading cause of blindness in the world. Although it is widely accepted that DR is driven by ischemia, the current grading of DR severity is based only on structural alterations such as the presence of abnormal retinal microvasculature in non-proliferative DR or angiogenesis in proliferative DR. As a result, most patients have already developed irreversible retinal functional impairment when they first receive their DR diagnosis. DR develops through progressively increasing capillary non-perfusion leading to insufficient blood supply to meet the metabolic demand of the inner retinal neurons. This causes retinal ischemia, which activates signaling pathways that promote angiogenesis and herald the proliferative phase of retinopathy. If not managed in a timely fashion, proliferative DR can ultimately lead to blindness. Therefore, non-invasive imaging of retinal metabolic rate of oxygen is expected to improve our understanding of DR pathophysiology as well as significantly enhance our ability to diagnose and manage high-risk DR. This proposal aims to maximize the likelihood of translation and integration of a novel visible-light optical coherence tomography or vis-OCT into clinical management of DR. We seek to design, develop, and optimize the first clinical-prototype vis-OCT instrument to quantify retinal metabolic rate of oxygen in normal human subjects as well as in patients with diabetes. We believe that the proposed technology has the potential to transform the existing clinical practice of DR from anatomy-based approach to a more sensitive and objective function-based approach. The proposed work is built on Opticent Health’s successful meeting the goals in the Phase I project and on close collaboration with leading clinician-scientists.

项目摘要 糖尿病视网膜病变（diabetic retinopathy，DR）是糖尿病的一种并发症，也是世界范围内致盲的主要原因之一。虽然 人们普遍认为DR是由缺血引起的，目前DR严重程度的分级仅基于 结构改变，如非增殖性DR中存在异常视网膜微血管，或 因此，大多数患者已经发展成不可逆的视网膜病变。 当他们第一次接受DR诊断时，他们的功能障碍。DR通过逐步发展 增加毛细血管的非灌注，导致血液供应不足以满足代谢的需求。 视网膜内层神经元这会导致视网膜缺血，从而激活信号通路， 血管生成并预示视网膜病变的增殖阶段。如果不及时处理， DR最终可能导致失明。因此，非侵入性视网膜氧代谢率成像是 预计将提高我们对DR病理生理学的了解，并显着提高我们的能力， 诊断和管理高风险DR。 该建议旨在最大限度地提高一种新型可见光光学器件的平移和集成的可能性。 相干断层扫描或vis-OCT用于DR的临床管理。我们寻求设计、开发和优化 第一台临床原型vis-OCT仪器，用于量化正常人视网膜氧代谢率 受试者以及糖尿病患者。我们相信，这项技术有潜力 将现有的DR临床实践从基于解剖的方法转变为更敏感和客观的方法， 基于功能的方法。拟议的工作是建立在Opticent Health成功实现目标的基础上的。 I期项目，并与领先的临床科学家密切合作。